NASDAQ: MPLT
MapLight Therapeutics, Inc.
Healthcare · Biotechnology
After hours: $14.42(+2.78%) · as of 7:47 PM ET
Per-share valuation inputs need verification
Event dated Mar 31, 2026Market-derived shares outstanding and recent statement shares differ materially. Per-share ratios and valuation outputs may be unreliable until the share base is verified. This sometimes appears with ADRs or provider share-count gaps.
Market Cap
$11.07M
52w High
$40.43
52w Low
$9.10
P/E
-3.06
Volume
2.15M
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock fell 23.5% over the last year. Free cash flow declined 92.81% over the trailing twelve months.
What the market seems to be pricing
The market appears to be responding to weaker operating momentum rather than only rerating the stock.
What would invalidate this read
Free cash flow fell 92.81% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Company profile
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders.
Valuation
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
6
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Sep 18, 2026
Q3 FY26 · EPS est -$1.33 · Revenue est —
View